



Using *Drosophila* cell-based technologies as
part of an *in vivo* study

Stephanie Mohr, PhD

fgr.hms.harvard.edu






What kinds of screens and cell assays are possible?


fgr.hms.harvard.edu

Publications page for specific examples

Pooled vs. Arrayed format screens





pooled format



arrayed format cell screens

Pooled vs. Arrayed format screens

Pooled	Arrayed
Reagent library introduced in bulk, at random	Reagents arrayed in 96- or 384-well plates
Relatively easy to generate new libraries (synthesis on a chip)	Relatively difficult to generate new libraries (synthesis or cloning, benefits from automation)
Assay period of weeks	Assay period of days
Assays require separation between non-hits and hits, e.g. viability, selection, FACS	Assays range from well-level analyses (total ATP, transcription reporters, etc.) to imaging
Positive 'hits' identified by next-generation sequencing (compare population at start to endpoint)	Positive 'hits' identified by looking up the plate and well on a spreadsheet or database



CSH Cold Spring Harbor Laboratory
bioRxiv
 THE PREPRINT SERVER FOR BIOLOGY



HOME | ABOUT | CONTACT | SEARCH

New Results

Pooled genome-wide CRISPR screening for basal and context-specific fitness gene essentiality in *Drosophila* cells






Raghuvir Viswanatha, Zhongchi Li, Yanhui Hu, Norbert Perrimon
 doi: <https://doi.org/10.1101/274464>

pooled screen to detect essential genes








Why pool? Use-case 1: cancer
therapeutics


Concept:




Approach:




Goal:




tumor suppressor gene
is non-functional




alive




another gene
is non-functional



alive




+ drug that inhibits
function of the other gene





dead, sick, or
stops dividing




Identification of TSC-specific drug targets using synthetic screening.





Benjamin E. Housden et al., *Sci. Signal.* 2015;8:rs9



Why pool? Use-case 2: sensitivity
or resistance to a treatment



essential genes
(drop outs)



genes for which
knockout confers resistance

optimize:
concentration

Pooled assays

- Outgrowth—essential genes (wildtype)
- Outgrowth—essential genes (mutant cell line)
- Outgrowth in presence of mild dose of toxin—sensitivity
- Selection (toxin, pathogen, etc.)—resistance
- Sort cells (e.g. with a GFP marker)


Libraries available at the DRSC

- Pooled CRISPR sgRNA library for knockout screens
- Pooled CRISPR sgRNA library for activation screens
- Arrayed double-stranded RNA (dsRNA) for RNAi
 - genome-wide
 - focused (kinases, transmembrane, RNA binding, etc.)
 - orthologs of human genes encoding proteins with known drugs (“FDA” gene list)
 - custom libraries
- Arrayed short hairpin RNA (shRNA) plasmids for VDA RNAi (poster #867)
- Arrayed UAS-miRNA plasmids and miRNA ‘sponges’
- Arrayed open reading frame (ORF) plasmids

Pooled vs. Arrayed format screens



Pooled	Arrayed
Reagent library introduced in bulk, at random	Reagents arrayed in 96- or 384-well plates
Relatively easy to generate new libraries (synthesis on a chip)	Harder to generate new libraries (synthesis or cloning, benefits from automation)
Assay period of weeks	Assay period of days
Assays require separation between non-hits and hits, e.g. viability, selection, FACS	Assays range from well-level analyses (total ATP, transcription reporters, etc.) to imaging
Positive 'hits' identified by next-generation sequencing (compare population at start to endpoint)	Positive 'hits' identified by looking up the plate and well on a spreadsheet or database

can re-array the DRSC collection to customize




luminescence

e.g. control vs. experimental
transcription reporter




cell or organelle
morphology





growth or division

e.g. total ATP,
survival over time





protein, RNA, and/or DNA
localization




fluorescence


e.g. protein vs.
phosphoprotein by Abs




host cell-pathogen
interactions



A Dipt-luc reporter construct enables a genome-wide screen for genes that mediate hypercapnic immune suppression.





liro Taneli Helenius et al. J Immunol 2016;196:655-667





luminescence

e.g. control vs. experimental
transcription reporter




cell or organelle
morphology





growth or division

e.g. total ATP,
survival over time





protein, RNA, and/or DNA
localization



fluorescence

e.g. protein vs.
phosphoprotein by Abs



host cell-pathogen
interactions






Image screens at DRSC: IN Cell 6000

- Bright field
- Epifluorescence
- Confocal



Libraries available at the DRSC

- Pooled CRISPR sgRNA library for knockout screens
- Pooled CRISPR sgRNA library for activation screens
- Arrayed double-stranded RNA (dsRNA) for RNAi
 - genome-wide
 - focused (kinases, transmembrane, RNA binding, etc.)
 - orthologs of human genes encoding proteins with known drugs (“FDA” gene list)
 - custom libraries
- Arrayed short hairpin RNA (shRNA) plasmids for VDA RNAi (poster #867)
- Arrayed UAS-miRNA plasmids and miRNA ‘sponges’
- Arrayed open reading frame (ORF) plasmids



Summary

- Cell study → follow up *in vivo* -or- in mammalian cells
- *in vivo* study → use cells to assign function
- Pooled-format screens (CRISPR-KO, CRISPR-OE)
- Arrayed-format screens (dsRNA) including image-based screens
- DRSC has genome-wide, focused, and custom libraries

- *Contact us for help at any stage!*

Acknowledgements

Norbert Perrimon

Raghuvir Viswanatha

Claire Yanhui Hu

Jonathan Zirin

DRSC/TRiP staff

Gabriel Amador

Limmond Ayisi

Verena Chang

Ryan Colbeth

Aram Comjean

Colby Devereaux

Luping Lu

Rong Tao

Eric Vogt

Donghui Yang-Zhou

Funding agencies

NIH-NIGMS

Howard Hughes Medical Institute

Dana Farber/Harvard Cancer Center

HMS Tools & Technology Program

Collaborators

Sue Celniker/BDGP (FlyBi Project)

Hugo Bellen (CRIMIC Project)

Amanda Simcox (cell lines project)



**Dana-Farber/Harvard
Cancer Center**



A Cancer Center Designated by the
National Cancer Institute